ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
Frequently asked questions
What sector does ViroGates A/S (VIRO) operate in?
ViroGates A/S belongs to the Healthcare sector and operates in the Medical Devices industry.
What is ViroGates A/S (VIRO) current stock price?
As of the latest data, ViroGates A/S stock price is DKK 9.80, with a previous close of DKK 9.45. ViroGates A/S gained DKK 0.35 in the last trading session, representing a 3.7% increase.
What is ViroGates A/S (VIRO) current market capitalization?
ViroGates A/S market cap is approximately 90.96 million.
What is ViroGates A/S (VIRO) Earnings Per Share (EPS)?
The trailing EPS is -DKK 1.24.
What is ViroGates A/S (VIRO) EBITDA?
ViroGates A/S EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.87 million.
Does ViroGates A/S (VIRO) pay dividends?
No. ViroGates A/S does not pay a dividend.
What is ViroGates A/S (VIRO) beta (volatility) score?
ViroGates A/S has a beta of 0.592, indicating lower volatility than the overall market.
